CLOPIVET 12.50 WATER SOLUBLE POWDER (Each gram (g) contains: Clopidol 125mg)

Indications

• Prevention of thromboembolic events in coronary artery disease
• Management of peripheral vascular disease
• Post-myocardial infarction therapy
• Reduction of stroke risk in high-risk patients

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing information, as specific doses are not provided in the BNF.

Adults: Refer to the BNF for specific dosing recommendations, as they may vary based on the condition being treated and patient characteristics.

Mechanism of action

Clopidol works by irreversibly inhibiting the ADP (adenosine diphosphate) receptor on platelets, which is essential for platelet activation and aggregation. By blocking this receptor, clopidol prevents the activation of the glycoprotein IIb/IIIa complex, thereby reducing platelet aggregation and the formation of blood clots. This action is critical in reducing the risk of thrombotic events in at-risk populations.

Pharmacodynamics

Clopidol exhibits its effects on platelet function by inhibiting the binding of ADP to its receptor, leading to decreased platelet aggregation and prolongation of bleeding time. The onset of action can vary, and full antiplatelet effects may not be observed until several days after initiation of therapy due to the irreversible nature of its action on the platelet receptors.

Pharmacokinetics

Clopidol is absorbed relatively quickly after oral administration, with peak plasma concentrations occurring within a few hours. The drug undergoes hepatic metabolism to active metabolites, which contribute to its antiplatelet effects. The elimination half-life of clopidol is approximately 8 to 12 hours, and it is primarily excreted in urine. Factors such as hepatic function can influence its pharmacokinetics, necessitating careful consideration in patients with liver impairment.

Contra-indications

• Hypersensitivity to clopidogrel or any of its components
• Active bleeding such as peptic ulcer or intracranial hemorrhage
• Severe liver impairment

Adverse effects

• Bleeding complications
• Gastrointestinal upset
• Rash
• Thrombocytopenic purpura
• Hepatic dysfunction

Interactions

• Caution with anticoagulants as they may increase the risk of bleeding
• Inhibitors of CYP2C19 may reduce the efficacy of clopidogrel
• NSAIDs may increase the risk of gastrointestinal bleeding when used concurrently

Precautions

• Monitor for signs of bleeding
• Use with caution in patients with a history of gastrointestinal bleeding
• Discontinue prior to surgery to reduce the risk of bleeding

Pregnancy

Clopidogrel should only be used in pregnancy when the benefits outweigh the risks, as there is limited data on its safety.

Breast-feeding

Clopidogrel is excreted in breast milk. Caution is advised and the benefits should be weighed against potential risks.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets